$ANAB News

AnaptysBio: Fully Valued -- With Major Litigation Uncertainty

AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story

AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise

JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup

GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control

AnaptysBio: The Royalty Waterfall Is About To Reverse

What Makes AnaptysBio (ANAB) an Investment Bet?

HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

Forte Biosciences: Targeting Celiac Disease